| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:47 UTC |
|---|
| HMDB ID | HMDB0014900 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Irinotecan |
|---|
| Description | Irinotecan, also known as HSDB 7607 or irinophore C, belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring). Irinotecan is a drug which is used for the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). also used in combination with cisplatin for the treatment of extensive small cell lung cancer. irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. . In humans, irinotecan is involved in the irinotecan action pathway. Irinotecan is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Irinotecan. |
|---|
| Structure | CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=C1C=C(OC(=O)N1CCC(CC1)N1CCCCC1)C=C2 InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (+)-Irinotecan | ChEBI | | HSDB 7607 | ChEBI | | Irinophore C | ChEBI | | Irinotecan lactone | ChEBI | | Irinotecan mylan | ChEBI | | Irinotecanum | ChEBI | | Biotecan | Kegg | | Irinotecan hydrochloride trihydrate | HMDB | | CPT-11 | HMDB | | sn38 CPD | HMDB | | 7-Ethyl-10-hydroxycamptothecin | HMDB | | Camptosar | HMDB | | Irrinotecan | HMDB | | Camptothecin-11 | HMDB | | Irinotecan hydrochloride | HMDB | | NK012 Compound | HMDB | | sn-38 | HMDB | | CPT 11 | HMDB | | sn 38 | HMDB | | 7 Ethyl 10 hydroxycamptothecin | HMDB | | CPT11 | HMDB | | Camptothecin 11 | HMDB |
|
|---|
| Chemical Formula | C33H38N4O6 |
|---|
| Average Molecular Weight | 586.678 |
|---|
| Monoisotopic Molecular Weight | 586.279134968 |
|---|
| IUPAC Name | (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate |
|---|
| Traditional Name | irinotecan |
|---|
| CAS Registry Number | 100286-90-6 |
|---|
| SMILES | CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=C1C=C(OC(=O)N1CCC(CC1)N1CCCCC1)C=C2 |
|---|
| InChI Identifier | InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1 |
|---|
| InChI Key | UWKQSNNFCGGAFS-XIFFEERXSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring). |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Alkaloids and derivatives |
|---|
| Class | Camptothecins |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Camptothecins |
|---|
| Alternative Parents | |
|---|
| Substituents | - Camptothecin
- Pyranopyridine
- Quinoline
- Piperidinecarboxylic acid
- 4-aminopiperidine
- Pyridinone
- Piperidine
- Pyridine
- Benzenoid
- Carbamic acid ester
- Tertiary alcohol
- Heteroaromatic compound
- Amino acid or derivatives
- Tertiary aliphatic amine
- Tertiary amine
- Carboxylic acid ester
- Lactam
- Lactone
- Carbonic acid derivative
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Carboxylic acid derivative
- Monocarboxylic acid or derivatives
- Hydrocarbon derivative
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Alcohol
- Carbonyl group
- Organic oxygen compound
- Organic nitrogen compound
- Organic oxide
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 222 - 223 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.11 g/L | Not Available | | LogP | 3.2 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.33 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.1912 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.08 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 108.1 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1808.4 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 149.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 208.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 159.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 124.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 361.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 418.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 468.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 809.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 470.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1389.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 274.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 316.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 421.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 315.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 32.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Irinotecan GC-MS ("Irinotecan,1TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Irinotecan GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Irinotecan GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Irinotecan LC-ESI-qTof , Positive-QTOF | splash10-0006-0091000000-b15811b1af58e71b3ec6 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Irinotecan , positive-QTOF | splash10-0006-0091000000-b15811b1af58e71b3ec6 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Irinotecan , positive-QTOF | splash10-000i-0101190000-eed1a0e57a719811aa8e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Irinotecan 35V, Positive-QTOF | splash10-000i-0200090000-b02dc01510d13cf037e7 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Irinotecan 35V, Negative-QTOF | splash10-0006-0000090000-f8b88d90efcda01ed933 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 10V, Positive-QTOF | splash10-00kr-0711190000-017c476dfdce0a695ded | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 20V, Positive-QTOF | splash10-014j-1913030000-900f8f5bcd9d41c35513 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 40V, Positive-QTOF | splash10-014i-4900000000-2609623f4a3366568329 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 10V, Negative-QTOF | splash10-000l-0301190000-9348778de404f9c838c4 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 20V, Negative-QTOF | splash10-0006-2915280000-3ff569c46ef34dfc85a4 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 40V, Negative-QTOF | splash10-03xr-3973100000-fa1a14e54424adaa488b | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 10V, Positive-QTOF | splash10-000i-0000090000-5a234f897e3e4b6515a3 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 20V, Positive-QTOF | splash10-000i-0100190000-7b0ab4e5fa02d64ba15a | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 40V, Positive-QTOF | splash10-02gk-4900010000-b6eab61080ef0a9d3fc8 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 10V, Negative-QTOF | splash10-000i-0000090000-ada5e1406bd27c1d2b44 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 20V, Negative-QTOF | splash10-000i-0000290000-fe55b707040cb6e249f1 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Irinotecan 40V, Negative-QTOF | splash10-001r-0312290000-ba4e4f01f6849a926d64 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501 ]
- Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077 ]
- Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15;22(8):1382-8. Epub 2004 Mar 8. [PubMed:15007088 ]
- O'Dwyer PJ, Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006 Oct 1;24(28):4534-8. [PubMed:17008691 ]
- (). FDA label . .
|
|---|